Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.105 USD | -0.45% | +49.45% | -20.71% |
Apr. 26 | Foreign automakers eager for Chinese partners at Beijing auto show | RE |
Apr. 25 | Battle for 'tech luxury' in China as EVs get smarter - and cheaper | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.71% | 168M | C+ | ||
-1.65% | 103B | B+ | ||
+6.75% | 101B | B+ | ||
+6.58% | 23.07B | B | ||
-12.60% | 22.23B | B+ | ||
-4.78% | 18.05B | A- | ||
-39.98% | 17.18B | A- | ||
-10.17% | 16.94B | B | ||
+6.12% | 14.07B | C+ | ||
+35.47% | 12.35B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MCRB Stock
- Ratings Seres Therapeutics, Inc.